{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026162","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.806321+00:00","generated_at":"2026-06-21T08:22:51.133586+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns","bullets":["Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.","Amy Burroughs appointed Class II director, term expiring at 2023 annual meeting.","Burroughs receives annual cash retainer of $35,000 plus $7,500 for audit committee; granted option for 40,000 shares vesting monthly over 3 years.","Burroughs is President & CEO of Cleave Therapeutics, brings >20 years healthcare/biotech experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026162","json":"https://secwatch.observer/filing/0000950170-22-026162.json","markdown":"https://secwatch.observer/filing/0000950170-22-026162.md","text":"https://secwatch.observer/filing/0000950170-22-026162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/tnya-20221205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:22:51.133586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59aff526a4","claim":"Eli Casdin resigned as Director at Tenaya Therapeutics, Inc..","evidence_excerpt":"On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5e0149dfdd","claim":"Amy Burroughs was appointed as Class II Director at Tenaya Therapeutics, Inc..","evidence_excerpt":"On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}